News | April 04, 2011

Wireless Remote Monitoring Program Launched to Help Congestive Heart Failure Patients

April 4, 2011 – A wireless remote monitoring program for patients with congestive heart failure (CHF) has been launched by Anthem Blue Cross. The program is designed to help patients better monitor and manage the condition.

Through the program, Anthem Blue Cross is utilizing wireless remote monitoring technology to provide real-time information to help those with CHF better manage their conditions and potentially prevent the need to return to the hospital. The company is undertaking this pilot program with members in California who have been diagnosed with CHF.

"We are passionate about developing state-of-the-art solutions for our members to help them better manage their health and to improve communication between them and their healthcare provider that can lead to greater coordination of care," said Kurt Tamaru, M.D., medical director with Anthem Blue Cross. "This is an exciting program as it combines wireless remote technology with clinically driven interventions to help deliver the right care at the right time and in a more effective and efficient way for our members."

Participants in the program who have a history of emergency room visits and hospitalizations will receive a wireless weight scale and blood pressure cuff to help them track their weight and blood pressure daily. Changes in weight and blood pressure are two key indicators of a potential change in their condition that may signal a more serious problem. The program will alert physicians of California PPO members when their patients gain weight that may be caused by fluid retention, which develops prior to patients becoming symptomatic. Identifying these individuals and enabling their doctors to treat their fluid retention in a timely manner, before shortness of breath develops, can prevent emergency room visits and subsequent acute hospital admissions.

The data collected from the monitoring devices is connected to an existing phone line and, using Bluetooth technology, is automatically populated to a secure Web portal that can be accessed by the member, physician, care giver and case manager. If irregularities in numbers occur, the member is contacted for the most appropriate action. Utilizing the latest home-monitoring technology, this program promotes better coordination and quality of care and earlier intervention to help get CHF under control.

For more information: www.anthem.com

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Overlay Init